Michael Platten is the winner of the “Breakthrough of the Year 2024” in the Life Sciences category of the Falling Walls Foundation.
Michael Platten's research has a major goal: He wants to advance the cure of one of the deadliest forms of brain tumors, known as gliomas. His work has shown that the immune system of patients can be mobilized with the help of novel vaccines against this form of cancer. The body's own defenses are then able to take very precise action against modified proteins that drive tumor growth. Michael Platten will be honored for his groundbreaking findings with the “Breakthrough of the Year 2024” award from the Falling Wall Foundation in Berlin on November 9, 2024.
Platten is head of the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center (DKFZ) and director of the Department of Neurology at the University Medical Center Mannheim (UMM). Since October, Platten has also been president of the European Association of Neuro-Oncology (EANO).
His involvement in clinical practice is an essential element of Platten's scientific success: “My inspiration comes primarily from the patients who struggle with this devastating disease every day,” says Platten. He believes it is of central importance that scientists develop solutions that bring real, tangible improvements to people's lives, the cancer researcher continues.
Breaking the wall of brain tumor vaccines
Clinical trials have already confirmed that his idea of activating the immune system with the help of vaccines against tumor cells works. In these trials, the vaccines proved to be safe and effective. The proof that his vaccine can trigger a targeted immune response in a patient's brain tumor was a breakthrough moment for him, says Platten.
Precision tumor therapy
What makes Platten's findings so special is the precision with which the immune system can attack cancer cells after activation by the novel vaccines: it recognizes tiny differences between normal proteins and those with cancer-causing mutations in their blueprint. His team has discovered that the so-called IDH1 mutation in particular plays a key role in many gliomas. This mutation occurs in almost 70 percent of low-grade, or slow-growing, gliomas.
The immunotherapy developed by Platten targets precisely this IDH1 mutation in order to generate a broad and effective immune response that encompasses all tumor cells, even if they differ genetically from one another. Cancer cells can thus be eliminated very specifically.
Application not only against brain tumors
Using advanced bioinformatics and molecular biology tools, his team has developed specific cellular immunotherapies that can potentially be used not only against brain tumors but also against other types of cancer. The idea behind this is that the identified mutations are present in all of a patient's tumor cells, which is crucial for the vaccines to be effective.
Platten also wants his research to inspire the next generation of scientists. His advice to young researchers is: “Be brave, ask questions, work in teams and share your knowledge. And if necessary, don't be afraid to break into completely new fields of research.”
Falling Walls Science Summit 2024
The title “Falling Walls Science Breakthrough of the Year” is awarded annually. It recognizes the most significant scientific breakthroughs in various categories of the Falling Walls Global Call. The winners present their groundbreaking work to a global audience at the Falling Walls Science Summit in Berlin on November 9, 2024.
Michael Platten is one of ten winners in the Life Sciences category and ultimately the winner of the Breakthrough of the Year 2024 in the Life Sciences.
His lecture can be followed online on November 9 from 5:15 to 5:30 p.m.:
https://falling-walls.com/foundation/people/michael-platten
The Falling Walls Science Summit will focus on topics such as artificial intelligence, renewable energies, quantum research and science diplomacy. Of particular importance is the question of how scientific breakthroughs can help to overcome the major global challenges of our time – climate change, health crises and technological upheaval.
The Berlin-based Falling Walls Foundation aims to bring together people “who want to tear down the next walls in science and society”. Since the first conference on the 20th anniversary of the fall of the Berlin Wall in 2009, Falling Walls has developed into a constantly growing network of the most ambitious and forward-thinking minds from around the world.
A photo of Michael Platten is available for download at:
https://www.dkfz.de/de/presse/pressemitteilungen/2024/bilder/Platten.jpg
Note on the use of image material for press releases
Use is free of charge. The German Cancer Research Center (DKFZ) permits use in connection with reporting on the topic of the press release or on the DKFZ in general. Please indicate as picture credits: “Source: J. Jung / DKFZ”.
The image may only be passed on to third parties after prior consultation with the DKFZ Press Office (Tel. 06221 42 2854, e-mail: presse@dkfz.de). Use for commercial purposes is prohibited.
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
National Center for Tumor Diseases (NCT, 6 sites)
German Cancer Consortium (DKTK, 8 sites)
Hopp Children's Cancer Center (KiTZ) Heidelberg
Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.